137 related articles for article (PubMed ID: 10337454)
21. Effect of sparfloxacin on Staphylococcus aureus adhesiveness and phagocytosis.
Desnottes JF; Diallo N
J Antimicrob Chemother; 1994 Apr; 33(4):737-46. PubMed ID: 8056692
[TBL] [Abstract][Full Text] [Related]
22. Correlation between reduction of surface hydrophobicity of S. aureus and the decrease in its adhesiveness induced by subinhibitory concentrations of brodimoprim.
Braga PC; Reggio S
Pharmacol Res; 1995 Nov; 32(5):315-9. PubMed ID: 8868063
[TBL] [Abstract][Full Text] [Related]
23. Protection of erdosteine on smoke-induced peripheral neutrophil dysfunction both in healthy and in bronchitic smokers.
Ciaccia A; Papi A; Tschirky B; Fregnan B
Fundam Clin Pharmacol; 1992; 6(8-9):375-82. PubMed ID: 1292969
[TBL] [Abstract][Full Text] [Related]
24. Effects on the reactive oxygen species of erdosteine and its metabolite in vitro.
Hosoe H; Kaise T; Ohmori K
Arzneimittelforschung; 2002; 52(6):435-40. PubMed ID: 12109043
[TBL] [Abstract][Full Text] [Related]
25. Interference by subinhibitory concentrations of azithromycin with the mechanism of bacterial adhesion to human epithelial cells.
Braga PC; Piatti G
Chemotherapy; 1993; 39(6):432-7. PubMed ID: 8222872
[TBL] [Abstract][Full Text] [Related]
26. Clinical effects of erdosteine in the treatment of acute respiratory tract diseases in children.
Balli F; Bergamini B; Calistru P; Ciofu EP; Domenici R; Doros G; Dragomir D; Gherghina I; Iordachescu F; Murgoci G; Orasanu D; Plesca D; Vaccaro A; Assereto R
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):16-22. PubMed ID: 17256446
[TBL] [Abstract][Full Text] [Related]
27. Influence of erdosteine, a mucolytic agent, on amoxycillin penetration into sputum in patients with an infective exacerbation of chronic bronchitis.
Ricevuti G; Mazzone A; Uccelli E; Gazzani G; Fregnan GB
Thorax; 1988 Aug; 43(8):585-90. PubMed ID: 3051508
[TBL] [Abstract][Full Text] [Related]
28. Depressant effects of ambroxol and erdosteine on cytokine synthesis, granule enzyme release, and free radical production in rat alveolar macrophages activated by lipopolysaccharide.
Jang YY; Song JH; Shin YK; Han ES; Lee CS
Pharmacol Toxicol; 2003 Apr; 92(4):173-9. PubMed ID: 12753420
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of erdosteine 900 versus 600 mg/day in reducing oxidative stress in patients with COPD exacerbations: Results of a double blind, placebo-controlled trial.
Dal Negro RW; Visconti M; Turco P
Pulm Pharmacol Ther; 2015 Aug; 33():47-51. PubMed ID: 26116425
[TBL] [Abstract][Full Text] [Related]
30. Protective effect of erdosteine metabolite I against hydrogen peroxide-induced oxidative DNA-damage in lung epithelial cells.
Marabini L; Calò R; Braga PC
Arzneimittelforschung; 2011; 61(12):700-6. PubMed ID: 22282957
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of bacterial adhesion by sub-inhibitory concentrations: brodimoprim vs trimethoprim.
Braga PC; Piatti G; Limoli A; Santoro M; Gazzola T
J Chemother; 1993 Dec; 5(6):447-52. PubMed ID: 8195836
[TBL] [Abstract][Full Text] [Related]
32. Protein oxidation and lipid peroxidation after renal ischemia-reperfusion injury: protective effects of erdosteine and N-acetylcysteine.
Erdogan H; Fadillioglu E; Yagmurca M; Uçar M; Irmak MK
Urol Res; 2006 Feb; 34(1):41-6. PubMed ID: 16429300
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of erdosteine against nephrotoxicity caused by gamma radiation in male albino rats.
Elkady AA; Ibrahim IM
Hum Exp Toxicol; 2016 Jan; 35(1):21-8. PubMed ID: 25716170
[TBL] [Abstract][Full Text] [Related]
34. [Effect of sub-inhibitory concentrations of cefixime on the morphology, hemagglutination and adhesiveness of urinary strains of Escherichia coli].
Desnottes JF; Diallo N; Loubeyre C
Presse Med; 1989 Oct; 18(32):1572-5. PubMed ID: 2530535
[TBL] [Abstract][Full Text] [Related]
35. Protective role of erdosteine on vancomycin-induced oxidative stress in rat liver.
Sahin M; Cam H; Olgar S; Tunc SE; Arslan C; Uz E; Yilmaz HR
Mol Cell Biochem; 2006 Oct; 291(1-2):155-60. PubMed ID: 16733804
[TBL] [Abstract][Full Text] [Related]
36. Erdosteine: Drug exhibiting polypharmacy for the treatment of respiratory diseases.
Dal Negro R; Pozzi E; Cella SG
Pulm Pharmacol Ther; 2018 Dec; 53():80-85. PubMed ID: 30352285
[TBL] [Abstract][Full Text] [Related]
37. Effects of erdosteine treatment against doxorubicin-induced toxicity through erythrocyte and plasma oxidant/antioxidant status in rats.
Fadillioğlu E; Erdoğan H
Pharmacol Res; 2003 Apr; 47(4):317-22. PubMed ID: 12644389
[TBL] [Abstract][Full Text] [Related]
38. Protective effect of erdosteine on erythrocyte deformability in a rat model of lower limb ischemia/reperfusion injury.
Özer A; Demirtaş H; Çomu FM; Erer D; Kılıç Y; Mardin B; Küçük A; Oktar GL
Turk J Med Sci; 2018 Feb; 48(1):187-190. PubMed ID: 29479982
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model.
Karateke A; Dokuyucu R; Dogan H; Ozgur T; Tas ZA; Tutuk O; Agturk G; Tumer C
Med Princ Pract; 2018; 27(6):515-522. PubMed ID: 30293079
[TBL] [Abstract][Full Text] [Related]
40. Protective effect of erdosteine against hypochlorous acid-induced acute lung injury and lipopolysaccharide-induced neutrophilic lung inflammation in mice.
Hayashi K; Hosoe H; Kaise T; Ohmori K
J Pharm Pharmacol; 2000 Nov; 52(11):1411-6. PubMed ID: 11186250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
